These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392 [TBL] [Abstract][Full Text] [Related]
4. [The reactogenicity and immunological efficacy of a Klebsiella vaccine in donors]. Kurbatova EA; Egorova NB; Dubova VG; Davatdarova GM; Lipats AA; Gervazieva VB; Kaverina KG Zh Mikrobiol Epidemiol Immunobiol; 1990 May; (5):53-6. PubMed ID: 2201154 [TBL] [Abstract][Full Text] [Related]
5. [Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. IV. The effect of immunization with Pseudomonas aeruginosa vaccine on the immune status of volunteer donors]. Titova TI; Sidorova TN; Radkevich SA; Antsiferova NG; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1985 Aug; (8):80-4. PubMed ID: 3933225 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293 [TBL] [Abstract][Full Text] [Related]
7. [Results of a study of the safety, reactogenicity and immunologic effectiveness of pyoimmunogen in the immunization of volunteer donors]. Krokhina MA; Grishina IA; Arkhipova NA; Zarubina EK; Edvabnaia LS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):95-8. PubMed ID: 7331614 [TBL] [Abstract][Full Text] [Related]
8. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Kim DK; Kim JJ; Kim JH; Woo YM; Kim S; Yoon DW; Choi CS; Kim I; Park WJ; Lee N; Jung SB; Ahn BY; Nam SW; Yoon SM; Choi WJ Vaccine; 2000 Dec; 19(9-10):1274-83. PubMed ID: 11137267 [TBL] [Abstract][Full Text] [Related]
9. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4]. Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515 [TBL] [Abstract][Full Text] [Related]
10. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model. Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242 [TBL] [Abstract][Full Text] [Related]
16. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120 [TBL] [Abstract][Full Text] [Related]
17. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165 [TBL] [Abstract][Full Text] [Related]
18. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Cryz SJ; Sadoff JC; Fürer E Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893 [TBL] [Abstract][Full Text] [Related]
19. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588 [TBL] [Abstract][Full Text] [Related]
20. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Jang IJ; Kim IS; Park WJ; Yoo KS; Yim DS; Kim HK; Shin SG; Chang WH; Lee NG; Jung SB; Ahn DH; Cho YJ; Ahn BY; Lee Y; Kim YG; Nam SW; Kim HS Vaccine; 1999 Jan; 17(2):158-68. PubMed ID: 9987150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]